Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors

Liver Transplantation

Volumn 14, Issue 1, 2008, Pages 66-72

  Bajjoka, Iman ^a   Hsaiky, Lama ^a   Brown, Kimberly ^a   Abouljoud, Marwan ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CLOTRIMAZOLE; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN; DEXAMETHASONE; DIPHENHYDRAMINE; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PIPERACILLIN PLUS TAZOBACTAM; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMODIALYSIS; HEPATITIS C; HUMAN; INCIDENCE; INJECTION SITE REACTION; KIDNEY FUNCTION; LEUKOPENIA; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ANIMALS; ANTILYMPHOCYTE SERUM; BIOPSY; CALCINEURIN; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RABBITS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 38649112647     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21309     Document Type: Article

References (32)

1. Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994;58:170-178.
2. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003;9:741-747.
3. Cabezuelo JB, Ramirez P, Acosta F, Sanchez Bueno F, Robles R, Pons JA, et al. Prognostic factors of early acute renal failure in liver transplantation. Transplant Proc 2002;34:254-255.
4. Moreno JM, Cuervas-Mons V, Rubio E, Pons F, Herreros de T A, Turrión VS, et al. Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transplant Proc 2003; 35:1907-1908.
5. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy. Transplantation 2001;72:1934-1939.
6. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998;66: 59-66.
7. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-940.
8. Paramesh AS, Roayaie S, Doan Y, Schwartz ME, Emre S, Fishbein T, et al. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant 2004; 18:94-99.
9. Campbell MS, Kotlyar DS, Bresinger CM, Lewis JD, Shetty K, Bloom RD, et al. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl 2005; 11: 1048-1055.
10. Bilbao I, Charco R, Balsells J, Lazaro JL, Hidalgo E, Llopart L, et al. Risk factors for acute renal failure after liver transplantation. Clin Transplant 1998; 12:123-129.
11. Gallardo ML, Gutierrez MEH, Perez GS, Balsera. EC, Ortega JFF, Garcia GQ. Risk factors for renal dysfunction in the postoperative course of liver transplant. Liver Transpl 2004; 10: 1379-1385.
12. Grande L, Rimola A, Cugat E, Alvarez L, Garcia-Valdecasas JC, Taurá P, et al. Effect of venovenous bypass on perioperative renal function in liver transplantation: results of a randomized, controlled trial. Hepatology 1996; 23:1418-1428.
13. Akamatsu N, Sugawara Y, Tamura S, Kaneko J, Togashi J, Kishi Y, et al. Prevention of renal impairment by continuous infusion of human atrial natriuretic peptide after liver transplantation. Transplantation 2005;80:1093-1098.
14. Biancofiore G, Della Rocca G, Bindi L, Romanelli A, Esposito M, Meacci L, et al. Use of fenoldopam to control renal dysfunction early after liver transplantation. Liver Transpl 2004; 10:986-992.
15. Della Rocca G, Pompei L, Costa MG, Coccia C, Scudeller L, Di Marco P, et al. Fenoldoparn mesylate and renal function in patients undergoing liver transplantation: a randomized, controlled pilot trial. Anesth Anale 2004;99:1604-1609.
16. Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil. regimen: a multicenter randomized clinical trial. Liver Transpl 2005; 11:1064-1072.
17. Hirose R, John R, Quan D, Osorio RW, Freise C, Ascher NL, et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000;69:307-311.
18. Tchervenkov JI, Tzimas GN, Cantarovich M, Barkun JS, Metrakos P. The impact of Thymoglobulin on renal function and calcineurin inhibitor initiation in recipients of orthotopic liver transplant: a retrospective analysis of 298 consecutive patients. Transplant Proc 2004;36:1747-1752.
19. Lin CC, Chuang FR, Lee CH, Wang CC, Chen YS, Liu YW, et al. The renal sparing efficacy of basilizimab in adult living donor liver transplantation. Liver Transpl 2005;11: 1258-1264.
20. Sellers MT, McGuire BM, Haustein SV, Bynon JS, Hunt SL, Eckboff DE. Two-dose daclizumab induction therapy in 209 liver transplants: a single-center analysis. Transplantation 2004;78:1212-1217.
21. Tector AJ, Fridell JA, Mangus RS, Shah A, Milgrom M, Kwo P, et al. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl 2004;10:404-407.
22. Knight RJ, Kerman RH, Schoenberg L, Podder H, Van Buren CT, Katz S, et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 2004; 78:904-910.
23. Shaffer D, Langone A, Nylander WA, Goral S, Kizllisik AT, Helderman JH. A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function. Clin Transplant 2003; 17(suppl 9):31-34.
24. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr. Steroid-free liver transplantation using rabbit anti-thymocyte globulin and early tacrolimus monotherapy. Transplantation 2003;75:1396-1399.
25. Brennan D, Daller J, Lake K. Rabbit antithymocyte globulin versus basiliximab for induction in renal transplantation. N Engl J Med 2006;355:9.
26. Brennan D, Flavin K, Lowell J, Howard TK, Shenoy S, Burgess S, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999;67:1011-1018.
27. Cantarovich D, Giral-Classe M, Hourmant M, Dantal J, Blancho G, Lerat L, et al. Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporine after renal transplantation. Nephrol Dial Transplant 2000;15:1673-1676.
28. Matas A, Kandaswamy R, Gillingham K, McHugh L, Ibrahim H, Kasiske B, et al. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant 2005;5:2473-2478.
29. Heffron TG, Smallwood GA, de Vera ME, Davis L, Martinez E, Stieber AC. Daclizumab induction in liver transplant recipients, Transplant Proc 2004;33:1527.
30. Emre S, Gondolesi G, Polat K, Ben-Haim M, Artis T, Fishbein TM, et al. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2001;7:220-225.
31. Bogetti D, Sankary HN, Jarzembowski TM, Manzelli A, Knight PS, Thielke J, et al. Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury. Clin Transplant 2005;19:507-511.
32. Muller TF. Thymoglobulin: a immunologic review. Curr Opin Organ Transplant 2003;8:305.